LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RVMD
Revolution Medicines, Inc.
There isn't enough reported data to score RVMD yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RVMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RVMD's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RVMD PE Valuation
RVMD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RVMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Moderate | |
| Low |
Analysts expect RVMD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RVMD on earnings quality, reporting a profit while its opponent remains loss making.
RVMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$9.15 | -$4.08 |
| Q2 2026 | -$8.86 | -$4.46 |
| Q1 2026 | -$7.11 | -$3.21 |
| Q4 2025 | -$5.95 | -$2.48 |
| Q3 2025 | -$5.07 | -$1.39 |
| Q2 2025 | -$4.40 | -$0.67 |
| Q1 2025 | -$3.90 | -$0.06 |
| Q4 2024 | -$3.47 | +$0.39 |
RVMD lost $9.15 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RVMD on profitability, with a higher operating margin.
RVMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $742K | -95% |
| Q2 2023 | $3.8M | -58% |
| Q1 2023 | $7M | -7.4% |
| Q4 2022 | $15.3M | +62% |
| Q3 2022 | $3.4M | +205% |
| Q2 2022 | $9.1M | +4.8% |
| Q1 2022 | $7.6M | -25% |
| Q4 2021 | $9.5M | +8.1% |
RVMD's revenue is growing: $198M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -189% | N/A |
| Q4 2023 | -24256% | -23854 points |
| Q2 2023 | -2845% | -2164 points |
| Q1 2023 | -1072% | -307 points |
| Q4 2022 | -403% | +157 points |
| Q3 2022 | -2280% | +2548 points |
| Q2 2022 | -681% | -169 points |
| Q1 2022 | -765% | -396 points |
RVMD's operating margin was −189% last quarter, up 214 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RVMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
RVMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$419.3M | -$208.7M |
| Q2 2026 | -$389.6M | -$160.4M |
| Q1 2026 | -$355.7M | -$158M |
| Q4 2025 | -$276.2M | -$136.7M |
| Q3 2025 | -$210.7M | -$76.7M |
| Q2 2025 | -$229.2M | -$98.6M |
| Q1 2025 | -$197.7M | -$34M |
| Q4 2024 | -$139.5M | -$16.6M |
RVMD has burned cash in almost every quarter: −$1.4B over the past year, against −$777M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RVMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RVMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +4.1M shares |
| 1 year | +14% | +25.7M shares |
| 3 years | +101% | +108M shares |
| 5 years | +193% | +142M shares |
| Available history | +489% | +178M shares |
RVMD has 215M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RVMD Net Leverage
RVMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RVMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.3 | Neutral |
| Stochastic | 22.2 | Neutral |
RVMD's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RVMD PE vs Healthcare Sector
RVMD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RVMD on trend strength, trading above more of its moving averages.
RVMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $190.8 | 7.6% below |
| 20 week MA | $194.8 | 9.5% below |
| 50 week MA | $147.8 | 19% above |
| 100 week MA | $95.6 | 85% above |
| 200 week MA | $64.3 | 174% above |
RVMD has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 174% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
RVMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.3 | $42.6 | +51% |
| 2021 | $42.6 | $27.6 | -35% |
| 2022 | $27.6 | $22.0 | -20% |
| 2023 | $22.0 | $28.7 | +30% |
| 2024 | $28.7 | $44.2 | +54% |
| 2025 | $44.2 | $80.8 | +83% |
| 2026 YTD | $80.8 | $176.4 | +118% |
RVMD has the edge over LLY on returns for 2026, with the stronger performance.